Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aradigm Corporation    ARDM

ARADIGM CORPORATION (ARDM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
1.58(c) 1.91(c) 1.71(c) 1.5692(c) 1.5399(c) Last
143 492 911 246 473 321 123 640 40 054 Volume
+11.27% +20.89% -10.47% -8.23% -1.87% Change
More quotes
Financials (USD)
Sales 2018 0,04 M
EBIT 2018 -12,4 M
Net income 2018 -16,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 584x
Capi. / Sales2019 -
Capitalization 23,4 M
More Financials
Company
Aradigm Corp. is a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists.Its technologies include diabetes and pain management, AERx essence devices.The... 
More about the company
Latest news on ARADIGM CORPORATION
04/18ARADIGM CORPORATION (NASDAQ : ARDM) Files An 8-K Entry into a Material Definitiv..
AQ
04/18ARADIGM CORP : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
04/12ARADIGM : Announces the EMA Has Completed Its Validation of the MAA Submission
AQ
04/09ARADIGM CORPORATION : Wired News – EMA Completed Validation of MAA for Aradigm’s..
AC
04/09ARADIGM : Announces the EMA Has Completed Its Validation of the MAA Submission
AQ
04/06ARADIGM : Linhaliq under EMA review for lung infection
AQ
04/05ARADIGM : Announces Fourth Quarter 2017 and Full Year Financial Results
AQ
04/05ARADIGM : Announces the EMA Has Completed Its Validation of the MAA Submission
BU
03/29ARADIGM CORPORATION (NASDAQ : ARDM) Files An 8-K Departure of Directors or Certa..
AQ
03/28ARADIGM : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/20Aradigm $ARDM Trading -3.1% Higher  
04/20Aradigm $ARDM Earns Media Sentiment Score of 0.15  
04/18Want the latest analyst ratings on $FSYS $PDS $CRI $ARDM $APEN? Get Them Deli.. 
04/17 WR David Bell attended the spring game on Saturday, but also chatted with h..
9
04/17Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/17/2018)  
More tweets
Qtime:100
News from SeekingAlpha
04/17HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (04/17/2018) 
04/06YOUR DAILY PHARMA SCOOP : Conatus Setback, Applied DNA Signs Agreement, Evolus A.. 
04/05EMA accepts Aradigm's marketing application for Linhaliq for certain lung inf.. 
03/23Aradigm net loss improves in Q4 
03/23Aradigm reports Q4 results 
Chart ARADIGM CORPORATION
Duration : Period :
Aradigm Corporation Technical Analysis Chart | ARDM | US0385054004 | 4-Traders
Technical analysis trends ARADIGM CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
John M. Siebert Executive Chairman, Chief Executive Officer & CFO
Frederick M. Hudson Director
Edwin Gordon Director
Robert A. Reed Vice President-CMC, Regulatory & Quality
Sector and Competitors
1st jan.Capitalization (M$)
ARADIGM CORPORATION-77.02%23
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998